Intestinal Microbiota in Postmenopausal Breast Cancer Patients and Controls

• Published in: Cancers 2021-12, Vol.13 (24), p.6200
• Main Authors: Aarnoutse, Romy, Hillege, Lars E, Ziemons, Janine, De Vos-Geelen, Judith, de Boer, Maaike, Aerts, Elvira M E R, Vriens, Birgit E P J, van Riet, Yvonne, Vincent, Jeroen, van de Wouw, Agnes J, Le, Giang N, Venema, Koen, Rensen, Sander S, Penders, John, Smidt, Marjolein L
• Format: Article
• Language: English
• Subjects: Antibiotics; Breast cancer; Cancer screening; Cancer therapies; Carcinogenesis; Chemotherapy; Community structure; Cyclophosphamide; Dialister; Endocrine therapy; ErbB-2 protein; Feces; Intestinal microflora; Intestine; Investigations; Mammography; Medical screening; Metabolism; Microbiota; Nutritional status; Patients; Post-menopause; Prebiotics; Probiotics; Relative abundance; rRNA 16S; Sensitivity analysis; Species richness; Statistical analysis; Veillonellaceae; Womens health
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13246200

Previous preclinical and clinical research has investigated the role of intestinal microbiota in carcinogenesis. Growing evidence exists that intestinal microbiota can influence breast cancer carcinogenesis. However, the role of intestinal microbiota in breast cancer needs to be further investigated. This study aimed to identify the microbiota differences between postmenopausal breast cancer patients and controls. This prospective cohort study compared the intestinal microbiota richness, diversity, and composition in postmenopausal histologically proven ER+/HER2- breast cancer patients and postmenopausal controls. Patients scheduled for (neo)adjuvant adriamycin, cyclophosphamide (AC), and docetaxel (D), or endocrine therapy (tamoxifen) were prospectively enrolled in a multicentre cohort study in the Netherlands. Patients collected a faecal sample and completed a questionnaire before starting systemic cancer treatment. Controls, enrolled from the National Dutch Breast Cancer Screening Programme, also collected a faecal sample and completed a questionnaire. Intestinal microbiota was analysed by amplicon sequencing of the 16S rRNA V4 gene region. In total, 81 postmenopausal ER+/HER2- breast cancer patients and 67 postmenopausal controls were included, resulting in 148 faecal samples. Observed species richness, Shannon index, and overall microbial community structure were not significantly different between breast cancer patients and controls. There was a significant difference in overall microbial community structure between breast cancer patients scheduled for adjuvant treatment, neoadjuvant treatment, and controls at the phylum ( = 0.042) and genus levels ( = 0.015). ( = 0.001) and its corresponding family Veillonellaceae ( = 0.001) were higher in patients scheduled for adjuvant treatment, compared to patients scheduled for neoadjuvant treatment. Additional sensitivity analysis to correct for the potential confounding effect of prophylactic antibiotic use, indicated no differences in microbial community structure between patients scheduled for neoadjuvant systemic treatment, adjuvant systemic treatment, and controls at the phylum ( = 0.471) and genus levels ( = 0.124). Intestinal microbiota richness, diversity, and composition are not different between postmenopausal breast cancer patients and controls. The increased relative abundance of and Veillonellaceae was observed in breast cancer patients scheduled for adjuvant treatment, which might be caused by a